Dr. Shankara Paneesha discussed the evolving treatment landscape for relapsed CLL, focusing on BTK resistance, new treatment options including cellular therapy, and the importance of patient-specific factors in treatment decisions.
This video covers the topic of diagnostic markers in CLL and is CME accredited for 0.25 credits (15 min).
0:24 - Introduction to CLL Treatment: Discussion on BTK resistance and new treatment options, including cellular therapy and T cell engagers.
1:33 - Factors Influencing Treatment Decisions: Patient-specific factors such as concurrent medical illnesses and drug interactions.
4:05 - Management of Relapsed CLL: Algorithm for managing relapsed CLL, including indications for treatment and prior treatment considerations.
9:22 - Clinical Trials and Guidelines: Summary of key clinical trials for BTK and BCL-2 inhibitors in the relapsed setting.
14:57 - BTK Resistance and Non-Covalent BTK Inhibitors: Explanation of BTK resistance mechanisms and management strategies.